Previous 10 | Next 10 |
A committee of the European Medicines Agency (EMA) recommended the approval of BeiGene ( NASDAQ: BGNE ) Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic leukemia (CLL). The positive opinion by the EMA's Committee for Medicinal Products...
If approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trials With significantly lower rates of atrial fibrillation/flutter compared to standard of care, BRUKINSA has potential to...
Also, positive top-line results released Wednesday from a phase 3 head-to-head trial indicating Brukinsa bested Imbruvica in terms of better progression-free survival in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma patients bodes well. Beigene has a...
BeiGene ( NASDAQ: BGNE ) said its medicine Brukinsa achieved superior progression free survival (PFS) compared to Johnson & Johnson ( NYSE: JNJ ) and AbbVie's ( NYSE: ABBV ) Imbruvica in certain patients with a type of blood cancer in a phase 3 trial...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA ® (zanubrutinib) achieved super...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Summary BeiGene Q2 revenue grew strongly and was significant. BeiGene’s approved therapies should continue to ramp revenue. Losing money due to high R&D costs is normal for a biotech at this stage. BeiGene ( BGNE ) is a Chinese biotechnology pharmaceut...
Summary These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infer...
BRUKINSA Is the First Bruton’s Tyrosine Kinase (BTK) Inhibitor Recommended by NICE for Routine Use for WM BRUKINSA Is the Only BTK Inhibitor Considered Cost Effective in WM BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology compan...
CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone lymphoma If approved, BRUKINSA will be t he first and only approved Bruton’s Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma in Europe BeiGene (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...